Analysts expect Genprex Inc (NASDAQ:GNPX) to announce earnings per share (EPS) of ($0.21) for the current quarter, Zacks reports. Zero analysts have issued estimates for Genprex’s earnings. Genprex reported earnings of ($0.45) per share during the same quarter last year, which suggests a positive year over year growth rate of 53.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 13th.
On average, analysts expect that Genprex will report full-year earnings of ($0.87) per share for the current financial year. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Genprex.
Genprex (NASDAQ:GNPX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.09.
NASDAQ:GNPX traded up $0.01 during mid-day trading on Friday, hitting $1.07. The company had a trading volume of 100 shares, compared to its average volume of 32,331. The business has a fifty day simple moving average of $1.38. Genprex has a 1 year low of $0.95 and a 1 year high of $7.95. The company has a market capitalization of $17.32 million, a price-to-earnings ratio of -1.18 and a beta of 1.49.
Genprex Company Profile
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.